Adult T-cell leukemia-lymphoma · 3 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Alemtuzumab monotherapy Variant #03 | — | R 267 680 | 7d | ~15.0 mo | — | ~1 | ~R 267 680 PFS proxy · indirect | — |
Lenalidomide monotherapy Variant #01 | — | R 2 178 | 28d | ~39.0 mo | ~113.8 mo | ~13 | ~R 28 314 PFS proxy · indirect | 10 |
Valemetostat monotherapy Variant #01 Partial | — | — | 28d | — | — | ~2 | — | — |
3 of 3 regimens shown